| Mr Henry Kyle Smith, DO | |
|
10413 S Yale Ave, Tulsa, OK 74137-6065 | |
| (717) 561-4940 | |
| (717) 561-4999 |
| Full Name | Mr Henry Kyle Smith |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 60 Years |
| Location | 10413 S Yale Ave, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487627238 | NPI | - | NPPES |
| 0628327 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 05002617L (Pennsylvania) | Primary |
| Entity Name | Smith Radiology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053384958 PECOS PAC ID: 7113965047 Enrollment ID: O20050421000438 |
News Archive
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
Teva Pharmaceutical Industries Ltd. today announced the publication of data from the 15-year clinical study with Copaxone® (glatiramer acetate injection), which is the longest prospective and continuous evaluation ever conducted in relapsing-remitting multiple sclerosis (RRMS) patients. The data were published in the February issue of the journal Multiple Sclerosis.
Considered one the great advances of modern medicine, electronic health records can provide a patient's entire medical history and a wealth of other information at the click of a button. They also have the potential to save countless lives and billions of dollars. Now, the University of Missouri has a two-year, $6.8 million cooperative agreement to help patients throughout the state benefit from increased use of this health information technology.
Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."
› Verified 2 days ago
| Entity Name | Eh Managment Company , Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487895918 PECOS PAC ID: 8325195183 Enrollment ID: O20090414000031 |
News Archive
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
Teva Pharmaceutical Industries Ltd. today announced the publication of data from the 15-year clinical study with Copaxone® (glatiramer acetate injection), which is the longest prospective and continuous evaluation ever conducted in relapsing-remitting multiple sclerosis (RRMS) patients. The data were published in the February issue of the journal Multiple Sclerosis.
Considered one the great advances of modern medicine, electronic health records can provide a patient's entire medical history and a wealth of other information at the click of a button. They also have the potential to save countless lives and billions of dollars. Now, the University of Missouri has a two-year, $6.8 million cooperative agreement to help patients throughout the state benefit from increased use of this health information technology.
Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Henry Kyle Smith, DO 945 E Park Dr, Ste 102, Harrisburg, PA 17111-2804 Ph: (717) 561-4940 | Mr Henry Kyle Smith, DO 10413 S Yale Ave, Tulsa, OK 74137-6065 Ph: (717) 561-4940 |
News Archive
Early detection of melanoma, the most aggressive skin cancer, is critical because melanoma will spread rapidly throughout the body. Now, University of Missouri researchers are one step closer to melanoma cancer detection at the cellular level, long before tumors have a chance to form. Commercial production of a device that measures melanoma using photoacoustics, or laser-induced ultrasound, will soon be available to scientists and academia for cancer studies.
Teva Pharmaceutical Industries Ltd. today announced the publication of data from the 15-year clinical study with Copaxone® (glatiramer acetate injection), which is the longest prospective and continuous evaluation ever conducted in relapsing-remitting multiple sclerosis (RRMS) patients. The data were published in the February issue of the journal Multiple Sclerosis.
Considered one the great advances of modern medicine, electronic health records can provide a patient's entire medical history and a wealth of other information at the click of a button. They also have the potential to save countless lives and billions of dollars. Now, the University of Missouri has a two-year, $6.8 million cooperative agreement to help patients throughout the state benefit from increased use of this health information technology.
Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."
› Verified 2 days ago
Jonathan Cross, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 5801 E 41st St Ste 900, Tulsa, OK 74135 Phone: 918-747-4975 Fax: 918-743-8552 | |
Dr. Kim R Hauger, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5801 E 41st St Ste 900, Tulsa, OK 74135 Phone: 918-747-4975 Fax: 918-743-8552 | |
Nina Jones, MD Radiology Medicare: Medicare Enrolled Practice Location: 4500 S Garnett Rd Ste 300, Tulsa, OK 74146 Phone: 918-728-6194 | |
Dr. Leila Danielle See, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 744 W 9th St, Tulsa, OK 74127 Phone: 981-599-5031 | |
Christopher Roman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4500 S Garnett Rd Ste 112, Tulsa, OK 74146 Phone: 918-935-3550 | |
Dr. Phillip Osborn Flinn, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 1120 S Utica Ave, Tulsa, OK 74104 Phone: 918-934-8347 Fax: 918-917-4114 | |
Shawn D Grant, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1120 S Utica Ave, Tulsa, OK 74104 Phone: 918-579-7720 |